Conclud

U.S. Serial No.: 09/693,908

binding, weak DNA binding and enhanced DNA binding as compared to the binding of said wild-type AAV Rep78-protein.

4. (Amended) The AAV Rep78 mutant of claim 2, wherein said AAV Rep78

modified protein having no DNA binding or weak DNA binding to said DNA sequence
and whivein file no DNA brudges
obtained from at least one of a papillomavirus, an AAV, an oncogene or a HIV, that results in
the generation of higher levels of AAV DNA replication and virion numbers compand

to the loves many wild type

5. (Amended) The AAV Rep78 mutant of claim 2, wherein said AAV Rep78 modified protein having enhanced DNA binding to said DNA sequence obtained from at least one of a papillomavirus or an oncogene that results in enhanced inhibition of at least one of a papillomavirus or an oncoprotein ampared to the Comespedent Wild hip.

03

13. (Amended) A fusion protein comprising an AAV Rep78 modified protein that binds to at least one DNA sequence obtained from one or more of a papillomavirus, an AAV, an oncogene or a HIV differently as compared to the binding of the corresponding wild-type AAV Rep78 protein as set forth in SEQ ID NO:6, and that results in AAV DNA replication and/or AAV virion production, wherein said different DNA binding is selected from the group consisting of no DNA binding, weak DNA binding and enhanced DNA binding as compared to the binding of said wild-type AAV Rep78 protein.

19. (Amended) A pharmaceutical composition comprising at least one AAV Rep78 mutant according to claim 2 with a pharmaceutically acceptable carrier.

46. (Amended) The AAV Rep78 mutant of claim 2, wherein said binding results oin AAV DNA replication and/or AAV virion production.

REMARKS

Claims 2, 4-20 and 46 are pending. Claims 3 and 46 are canceled without prejudice or disclaimer and applicant reserves the right to file one or more continuing applications on any canceled subject matter. Claim 2 is amended to more clearly define the present